Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...

The mRNA technology behind coronavirus vaccines is now being used to create bespoke vaccines for cancer patients.

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...

The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how to increase uptake. mRNA vaccine research may be on the chopping block, too.

Truist analyst Asthika Goonewardene lowered the firm’s price target on BioNTech (BNTX) to $151 from $172 and keeps a Buy rating on the shares.

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

U.S.-listed shares of BioNTech SE ended Monday nearly 3.2% lower, weighed down by a weak full-year revenue projection even as ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against the other best vaccine stocks to buy now. On February 24, CNBC reported that President Trump declared ...

The phase 1 study tested autogene cevumeran (BNT122, RO7198457), a therapeutic mRNA cancer vaccine developed and researched through a collaboration between BioNTech, an immunotherapy company, and ...

A new im­munol­o­gy biotech closed its Se­ries A, and it’s backed by in­vestors in­tri­cate­ly fa­mil­iar with the in­dus­try.